Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Latest Eisai Inc. Stories

2014-01-02 08:23:03

FYCOMPA is the First and Only FDA-Approved Non-Competitive AMPA Glutamate Receptor Antagonist WOODCLIFF LAKE, N.J., Jan. 2, 2014 /PRNewswire/ -- Eisai Inc. announced today that FYCOMPA(TM) (perampanel) CIII will be available to eligible patients by prescription in the U.S. beginning January 6, 2014. FYCOMPA is an adjunctive therapy for the treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy age 12 years and older. FYCOMPA is...

2013-12-09 12:25:55

Seeking indication for prevention of chemotherapy-induced nausea and vomiting LUGANO, Switzerland and WOODCLIFF LAKE, N.J., Dec. 9, 2013 /PRNewswire/ -- Helsinn Group and Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) accepted for review the submission of the New Drug Application (NDA) for the investigational oral fixed-dose combination capsule of netupitant 300 mg + palonosetron 0.50 mg (NEPA) for prevention of acute and delayed...

2013-12-05 08:29:48

WOODCLIFF LAKE, N.J., Dec. 5, 2013 /PRNewswire/ -- Today, Eisai Inc. announced that 16 abstracts highlighting new data analyses on FYCOMPA (perampanel) will be presented at the 67(th) annual American Epilepsy Society (AES) meeting, taking place in Washington, D.C. from December 6 - 10. (Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO) "These data analyses highlight Eisai's clinical research with FYCOMPA, reinforcing our commitment to the epilepsy community," said Lynn Kramer,...

2013-12-04 08:29:53

WOODCLIFF LAKE, N.J., Dec. 4, 2013 /PRNewswire/ -- Eisai Inc. announced today that five abstracts highlighting new study results will be presented during the 2013 San Antonio Breast Cancer Symposium. The meeting will be held December 10-14, 2013 at the Henry B. Gonzalez Convention Center in San Antonio, TX. (Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO ) The studies highlight Eisai's current and ongoing clinical research efforts with eribulin mesylate, and reinforce the...

2013-12-03 08:27:38

"Medikidz Explain Epilepsy" Aims to Help Children Better Understand the Disease WOODCLIFF LAKE, N.J., Dec. 3, 2013 /PRNewswire/ -- Eisai Inc., a leader in the epilepsy community, is proud to announce the availability of a first-of-its-kind comic book in the U.S. designed to educate children about epilepsy, a neurological condition that affects approximately 2.2 million people in the United States. "Medikidz Explain Epilepsy" tells a fictional story based on the experiences of...

2013-11-18 08:30:17

Representatives Will Use Educational Tool for Up to 65,000 Physicians WOODCLIFF LAKE, N.J. and BENSALEM, Pa., Nov. 18, 2013 /PRNewswire/ -- Eisai and BusinessOne Technologies announced today that Eisai Inc. is using the Maestro Market Access Mobile(TM) application to educate physicians about detailed coverage levels for Eisai's recently approved BELVIQ(®) (lorcaserin HCI) CIV. Market Access Mobile enables fact-based decisions and targeted strategies to increase clinical adoption and expand...

2013-11-18 08:28:37

WOODCLIFF LAKE, N.J. and SAN DIEGO, Nov. 18, 2013 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that a new data analysis from the BELVIQ(®) (lorcaserin HCl) Phase 3 clinical trial program will be presented at the American Heart Association 2013 Scientific Sessions, November 16-20 in Dallas, Texas. The following abstract highlighting BELVIQ data will be presented: -- The Effects of Lorcaserin on High-Sensitivity C-reactive Protein in...

2013-11-13 16:26:48

WOODCLIFF LAKE, N.J. and SAN DIEGO, Nov. 13, 2013 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc., (NASDAQ:ARNA) announced today that five abstracts highlighting new data analyses from the BELVIQ(®) (lorcaserin HCl) Phase 3 clinical trial program will be presented during ObesityWeek(SM) 2013, hosted by The Obesity Society and the American Society for Metabolic and Bariatric Surgery. ObesityWeek(SM) 2013 is taking place November 11-16 in Atlanta, Georgia. The following abstracts...

2013-11-13 08:29:04

Eisai to Convene Multidisciplinary Expert Panel in an Effort to Combat Growing Epidemic WOODCLIFF LAKE, N.J., Nov. 13, 2013 /PRNewswire/ -- A new survey conducted by Eisai Inc., in partnership with the Obesity Action Coalition (OAC) and The Obesity Society (TOS), reveals a disconnect between patients and physicians when discussing weight loss. The survey found that only 56 percent of overweight or obese adults report ever having discussed weight with their doctor, yet all physicians surveyed...

2013-11-08 08:28:25

WOODCLIFF LAKE, N.J., Nov. 8, 2013 /PRNewswire/ -- Eisai Inc. announced today that ACIPHEX(®) Sprinkle(TM) Delayed-Release Capsules 5mg and 10mg will be available to eligible patients by prescription in the United States by November 8, 2013. (Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO ) ACIPHEX Sprinkle Delayed-Release Capsules 5mg and 10mg was approved by the U.S. Food and Drug Administration on March 26, 2013 for the treatment of Gastroesophageal Reflux Disease (GERD) in...